PubMed Health⌕ Search

Biomedical subjects

R Colle

Publications and source records attributed to R Colle.

28 records · Page 2Linked to original sources
PubMed1978

[ Long-term evaluation of the effect of a chemotherapy protocol using vincristine, adriamycin, procarbazine and prednisone (VAPP) on advanced Hodgkin's disease].

A chemotherapeutic combination associating vincristine, adriamycin, procarbazine and prednisone (VAPP) was evaluated in Hodgkin's disease. Subjects were either far advanced cases or relapsing after MOPP and/or radiation therapy. 50 cases were evaluable. After 6 months of treatment 80% of the cases achieved a complete remission. After 30 months 87% of the patients still survive and 60% were still in complete remission. The good tolerance of this chemotherapeutic combination and the results described above, suggest that VAPP may be useful in all cases when MOPP is not well tolerated or is not active.

Adolescent↗
PubMed1975

[Current problems in therapy of evolutive malignant granuloma. Our experience with a new scheme of polychemotherapy].

Treatment of advanced Hodgkin's disease by associating vincristine, adriblastine, prednisone and procarbazine is compared with other widely employed protocols. Most subjects in the series had already received one or more drugs and had relapsed. In spite of this, 60% were still in complete remission one year after the administration of 6 courses of the new association. An account is given of maintenance therapy in Hodgkin's disease once remission is obtained, and the problems thus raised are illustrated.

Antineoplastic Agents↗
PubMedDate not supplied

Insect antifeedant activity and hot taste for humans of selected natural and synthetic 1,4-dialdehydes.

The antifeedant activity towards larvae of Leptinotarsa decemlineata and Spodoptera littoralis and the hot taste for the human tongue have been determined for natural and synthetic 1,4-dialdehydes. Among the bicyclic dialdehydes the biological activity has been found to be dependent on the distance between the two aldehyde groups; tricyclic and pentacyclic dialdehydes are inactive in both tests. A short synthetic route to (-)- and (+)-polygodial is reported.

Aldehydes↗
PubMedDate not supplied

Effectiveness of leukocyte interferon in patients affected by HCV-positive mixed cryoglobulinemia resistant to recombinant alpha-interferon.

OBJECTIVE: Interferon is the first-choice therapy for HCV-positive mixed cryoglobulinemia, but only a small fraction of the patients show long-term recovery from the disease. In non-responders or relapsers, the second-line therapy (high dose interferon) generally is not effective. The aim of this study was to evaluate the effectiveness of leukocyte interferon as a second-line therapy in patients who are non-responders or relapsers to a first course of recombinant interferon. METHODS: Twenty-eight patients with HCV-positive mixed cryoglobulinemia were enrolled. In each case the HCV-RNA and HCV genotype, as well as the usual laboratory parameters, were determined before, at the end of therapy and 1 year after the end of therapy. All patients were treated following the same schedule: leukocyte interferon 3,000,000 three times a week for one year. RESULTS: Only 5 patients obtained complete recovery from viral infection as well as from all signs and symptoms of the disease. Most patients (80%) experienced relief from clinical symptoms without recovery from HCV replication. Responders to the second interferon course were "relapsers" to the first treatment. No patient considered as a "non-responder" showed complete remission from the disease after the second treatment. CONCLUSIONS: A second leukocyte interferon course could be useful for patients affected by mixed crvoglobulinemia who relapsed after a first course of recombinant interferon therapy.

Adult↗
PubMedDate not supplied

Effects of two different alpha-interferon regimens on clinical and virological findings in mixed cryoglobulinemia.

OBJECTIVE: As previous studies have shown a good response of mixed cryoglobulinemia (MC) to alpha-interferon (IFN) therapy, we investigated the efficacy and tolerability of two IFN regimens in a group of 36 patients affected by MC. METHODS: The patients, diagnosed on the basis of standard clinical and laboratory criteria, were randomly divided into 2 groups: group A (18 cases) received alpha 2b-IFN 3 M.U. thrice a week for six months, while group B (18 cases) received alpha 2b-IFN thrice a week for 1 year. The patients were followed for six months after the end of therapy. Liver function tests, cryoglobulin determinations and a clinical examination were performed each month. HCV serology and HCV-RNA detection by PCR were performed before therapy and at the end of the follow-up period. RESULTS: The two study groups were comparable in age, male/female ratio, purpura score, cryoglobulin level, mean ALT serum activity and liver histology. 32 patients (89%) were positive for anti-HCV antibodies and 29 (81%) for HCV-RNA. During therapy all patients showed a significant (p < 0.001) decrease in their cryoglobulin level as well as improvement (p < 0.05) in their purpura score. In group A, five patients (28%) showed normalized ALT, but three later relapsed. In group B seven patients (39%) responded to treatment but three relapsed after suspension of the drug. Two patients from group B developed severe side effects (hypothyroidism and depression) and therapy was discontinued after 9 and 11 months, respectively. In all the non-responders and relapsed patients, purpura, ALT, and cryoglobulins rose to pre-treatment levels within a few months. At the end of follow-up, two patients from group A (11%) and four in group B (22%) had achieved complete remission. CONCLUSION: This study indicates that IFN is useful in MC and that viral replication can be considered the target of the therapy. Despite the absence of a statistical difference in the response rate between the two regimens (due to the low number of subjects), the one-year therapy course seemed to show a better efficacy, although associated with higher toxicity.

Adult↗